Proposed US rules on drug detention may pose new risk during inspections
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration has issued a proposed regulation that would provide FDA officers conducting inspections with the administrative authority to detain drugs that they believe are either adulterated or misbranded1.